Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunologic approach to herpes simplex virus.

R J Whitley1, R L Miller

  • 1University of Alabama at Birmingham, Department of Pediatrics, Microbiology and Medicine, Children's Hospital, 35233, USA. rwhitley@peds.uab.edu

Viral Immunology
|June 12, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of human coronavirus infections on paediatric patients at a tertiary paediatric hospital: a retrospective study of the prepandemic era.

The Journal of hospital infection·2023
Same author

Foreword.

Perspectives in medical virology·2020
Same author

Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines.

Gene therapy·2014
Same author

Case definitions, diagnostic algorithms, and priorities in encephalitis: consensus statement of the international encephalitis consortium.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2013
Same author

Treatment of herpes simplex virus infections in pediatric patients: current status and future needs.

Clinical pharmacology and therapeutics·2010
Same author

Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors.

Cancer gene therapy·2006
Same journal

Reovirus Reassortants Reveal Context-Dependent Oncolytic Phenotypes Across Epithelial Cancer Cell Lines.

Viral immunology·2026
Same journal

Syncytia Formation in the Pathogenesis of SARS-CoV-2 Infection: Lessons from Viral Infections.

Viral immunology·2026
Same journal

Screening and Characterization of Nanobody Against the Emerging Dairy Cattle H5N1 Influenza Virus.

Viral immunology·2026
Same journal

Immunoinformatics-Driven Design of a Multiepitope Vaccine for Rustrela Virus-Induced Neurological Diseases: A New Frontier in Encephalitis and Meningoencephalitis Prevention.

Viral immunology·2026
Same journal

Single-Cell Transcriptomic Profiling Reveals Molecular Alterations in the Airway Epithelial Cells of Children with Wheezing Infected by Respiratory Syncytial Virus.

Viral immunology·2026
Same journal

Effect of Pentoxifylline on Inflammatory Markers in COVID-19: A Meta-Analysis of Randomized Controlled Trials.

Viral immunology·2026
See all related articles

Herpes simplex virus (HSV) establishes latency and reactivates despite immune responses. Immune response modifiers (IRMs) show promise for treating recurrent genital herpes, a prevalent sexually transmitted disease.

Area of Science:

  • Virology
  • Immunology
  • Public Health

Background:

  • Herpes simplex virus (HSV) establishes lifelong latency and can reactivate, causing recurrent infections.
  • Genital herpes is a major global sexually transmitted disease, necessitating effective treatments.
  • Host immune responses are present but insufficient to prevent recurrent HSV infections.

Purpose of the Study:

  • To review the immunological control of primary and recurrent HSV infections.
  • To discuss current immune-based therapeutic strategies for HSV.
  • To explore the potential of immune response modifiers (IRMs) in treating HSV.

Main Methods:

  • Literature review of immunological control mechanisms.
  • Analysis of existing immune-based therapeutic approaches.

Related Experiment Videos

  • Discussion of preclinical and clinical data on IRMs.

    • Main Results:

    • HSV latency and reactivation are key features, occurring despite host immunity.
    • Current therapies for recurrent HSV are limited.
    • Immune response modifiers (IRMs) demonstrate potential in early studies.

    Conclusions:

    • Understanding HSV immunology is crucial for developing effective treatments.
    • Novel immune-based therapies, including IRMs, are needed to manage recurrent HSV infections.
    • IRMs offer a promising avenue for future HSV treatment strategies.